In short Article

New product form: Calcipotriol/betamethasone aerosol foam for psoriasis

Enstilar® (Leo Pharma, Denmark), aerosol foam for cutaneous use

Calcipotriol/betamethasone aerosol foam 0.05mg/g and 0.5 mg/g (Enstilar®) were registered in 2016 for the ‘local treatment of psoriasis vulgaris in adults’. The combination of calcipotriol and betamethasone has been in use for many years in primary care as an ointment or gel for the treatment of mild forms of psoriasis. Research has shown that the aerosol foam works better than the ointment and gel, though the differences are small. It is unclear whether these differences are clinically relevant. A striking aspect is that Enstilar® came on the market at the same moment at which the patent for proprietary calcipotriol/betamethasone ointment ran out and a generic ointment became available.

  • Research has shown that calcipotriol/betamethasone aerosol foam works better than calcipotriol/betamethasone ointment or gel.
  • The differences bwteen the aerosol foam and the ointment/gel are small, and the foam is more expensive. It is questionable whether this difference in effectiveness, of unclear clinical relevance, justifies the higher costs.
  • The manufacturer has reported that the aerosol foam is easier to use for patients, but there is no research evidence to prove this claim.
  • In view of the minor difference in effectiveness and the unclear clinical relevance, the drug rating for this agent is ‘+/-’.

  1. Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Østerdal ML, Stein Gold L. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015 Dec;14(12):1468-77.
  2. Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, J Bagel J. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study. J Dermatolog Treat, 2016; 27(2): 120–7.
  3. Paul C, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Bang B, Griffiths CE. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):119–126.
  4. College ter Beoordeling van Geneesmiddelen. Productinformatie Enstilar®. Via:
  5. College ter Beoordeling van Geneesmiddelen. Productinformatie Dovobet®. Via:
  6. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012 Mar;66(3):369-75.
  7. Michiels B. Relatief risico versus odds ratio. Minerva 2014; 13 (6): 77. Via:
  8. Mekkes JR. Finger Tip Unit (FTU). 2018 Via:
  9. Z-Index. G-Standaard. Via: KNMP-Kennisbank. KNMP, augustus 2019.
  10. Zorginstituut Nederland ( Aantal gebruikers -2017 van calcipotriol/betamethason.. Raming voor de totale Zvw-populatie 2017. Via:
  11. Griffiths EMG, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Møller A, et al. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. Eur J Dermatol. 2018;28(3):356-63.
  12. Informatorium Medicamentorum. Den Haag: KNMP, 2019. Via: knmp-kennisbank.
  13. Goodman&Gilman’s The pharmacological basis of therapeutics 13th edition. Brunton LL, Hilal-Dandan R, Knollmann BC. New York: Mc Graw Hill Medical, 2018.
  14. Van Peet PG, Spuls PhI, Ek JW, Lantinga H, Lecluse LLA, Oosting AJ, Visser HS, Burgers JS, Geijer RMM, Kolnaar BGM, Eizenga WH. NHG-Standaard Psoriasis(derde herziening). Huisarts Wet. 2014;57(3):128-35.

*The literature refers to the Dutch text


  • Leo M.L. Stolk